Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Prospective Clinical Study to Assess Clinical Performance of QIAstat-Dx® Respiratory Panel Plus (RPP) SARS-CoV-2 Target in the Intended Use Population and Environment

NCT05733559 is registered in ClinicalTrials.gov with QIAGEN Gaithersburg, Inc as lead sponsor.

NCT NCT05733559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05733559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Prospective Clinical Study to Assess Clinical Performance of QIAstat-Dx® Respiratory Panel Plus (RPP) SARS-CoV-2 Target in the Intended Use Population and Environment
Lead sponsor
QIAGEN Gaithersburg, Inc
Phase
Observational
Overall status
Completed
Start date
February 23, 2023
Completion date
October 11, 2023
Enrollment
565 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory disease